A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate
A phase 3 trial of Xaluritamig, Abiraterone acetate, Docetaxel in prostate cancer, run by Amgen, now recruiting.
Overview
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT07213674 by Amgen, with 750 participants planned, started 2025-11-28 and due to reach its primary completion in 2030-01-07. Interventions recorded: Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialXALute
Shares Xaluritamig, Cabazitaxel, Prostate cancer.
- TrialSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Shares Cabazitaxel, Docetaxel, Prostate cancer.
- TrialA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Abiraterone acetate, Docetaxel, Prostate cancer.
- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares Cabazitaxel, Abiraterone acetate, Prostate cancer.
- TrialPEACE-1
Shares Abiraterone acetate, Docetaxel, Prostate cancer.
- TrialThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Shares Abiraterone acetate, Docetaxel, Prostate cancer.
- TermPSA50 / PSA90 response
Shares Xaluritamig, Prostate cancer.
- TrialStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Shares Abiraterone acetate, Docetaxel, Prostate cancer.